Haleon (NYSE:HLN) Stock Moved Down to “Hold” by Wall Street Zen

Wall Street Zen lowered shares of Haleon (NYSE:HLN) from a buy rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also issued research reports about the stock. Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Thursday, August 6th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Wednesday, September 9th. Finally, Zacks Research upgraded Haleon from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Haleon presently has a consensus rating of “Moderate Buy”.

Haleon Stock Up 0.9%

NYSE:HLN opened at $8.79 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. Haleon has a 1-year low of $8.65 and a 1-year high of $11.28. The company has a 50-day moving average of $9.65 and a 200 day moving average of $9.55. The firm has a market cap of $38.68 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 1.99 and a beta of 0.14.

Haleon Cuts Dividend

The company also recently declared a dividend, which was paid on Thursday, September 17th. Stockholders of record on Friday, August 14th were issued a $0.0642 dividend. The ex-dividend date was Friday, August 14th. This represents a dividend yield of 132.0%. This is a decrease from Haleon’s previous dividend of $0.1307. Haleon’s dividend payout ratio (DPR) is 30.77%.

Institutional Investors Weigh In On Haleon

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Western Wealth Management LLC acquired a new stake in shares of Haleon in the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC boosted its position in Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after buying an additional 2,404 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Haleon by 20.4% in the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after buying an additional 1,055 shares during the last quarter. Fiduciary Financial Group LLC acquired a new position in Haleon in the 2nd quarter worth approximately $97,000. Finally, Gryphon Financial Partners LLC acquired a new position in Haleon in the 1st quarter worth approximately $101,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.